Manufacturer record
Skymap Pharmaceuticals Pvt. Ltd: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
29 batches manufactured by Skymap Pharmaceuticals Pvt. Ltd (Uttarakhand) were declared Not of Standard Quality between February 2020 and July 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
29 records linked to Skymap Pharmaceuticals Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
0Banned or prohibited
0Recalled or suspended
29Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
29
NSQ batches since 2020
24
Products affected
Dissolution
Most common failure
Jul 2026
Latest alert
Flagged batches per year
2020 · 22021 · 62022 · 62023 · 52024 · 32025 · 22026 · 5
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Pantoprazole Gastro-resistant Tablets IP | GD25214Mfg 2025-12 · Exp 2027-11 | TEST FOR DISSOLUTIONDissolution | DTL, DelhiState lab | Jul 2026 |
| Glipizide Tablets IP | SPA252473Mfg 2025-11 · Exp 2027-10 | Does not conform to IP Standards with respect to Dissolution TestDissolution | Food & Drugs Laboratory Bambolim, GoaState lab | Jul 2026 |
| Ofloxacin Tablets IP | SPA252289Mfg 2025-10 · Exp 2028-09 | Failed Dissolution testDissolution | DTL, PuducherryState lab | Jun 2026 |
| Cefixime Dispersible Tablets IP 200 mg | AB24069Mfg 2024-11 · Exp 2026-10 | MisbrandedMisbranded | SDTL, UttarakhandState lab | May 2026 |
| Pepsin & Fungal Diastase Syrup | SPA250909Mfg 2025-04 · Exp 2026-09 | The sample does not conform to Manufacturer's Specification with respect to Test for Identification and Assay of Pepsin activityAssay | CDL, KolkataCDSCO lab | Apr 2026 |
| Pantoprazole Gastro-Resistant Tablets IP (Pantoziv 40) | GD24157Mfg 2024-09 · Exp 2026-08 | Dissolution in Buffer Stage for PantoprazoleDissolution | RDTL, GuwahatiCDSCO lab | Jul 2025 |
| Calagy ( Calamine Lotion I.P.) | SPA243 098Mfg 2024-10 · Exp 2026-09 | Sample does not conforms to clain as per I.P. 2022 w.r.t. assay of Zinc OxideAssay | State labState lab | Mar 2025 |
| Ofloxacin Ornidazole Tablets IP | AD24059Mfg 2024-04 · Exp 2026-03 | Note: the sample received does not conformtoi.p.2022 specification with respect to the test for dissolution for the content of ofloxacin and ornidazole ( s1, s2 and s3 level) only. Cdtlh report no.: cdtlh/0131/f -Dissolution | CDTL HyderabadCDSCO lab | May 2024 |
| LactuloseSolution U.S.P. | GA2312 7Mfg 2023-11 · Exp 2025-10 | The sample does not conforms to claim as per U.S.P.in respect to the Assay.Assay | CDL KolkataCDSCO lab | May 2024 |
| Metoprolol Tablets IP 25 mg | GM23018Mfg 2023-07 · Exp 2025-06 | Related SubstancesRelated substances | CDTL MumbaiCDSCO lab | Mar 2024 |
| Diltizem Tablets IP 60mg | GM23005Mfg 2023-03 · Exp 2025-02 | Related SubstancesRelated substances | CDTL MumbaiCDSCO lab | Dec 2023 |
| Diltiazem Tablets IP 30 mg | GM22021Mfg 2022-04 · Exp 2024-03 | Related SubstancesRelated substances | CDTL MumbaiCDSCO lab | Sep 2023 |
| Metopal ? 50 XL (Metoprolol Succinate Extended Release Tablets IP) | JD22036Mfg 2022-06 · Exp 2024-05 | Dissolution & Assay of Metoprolol SuccinateAssay | CDL KolkataCDSCO lab | Apr 2023 |
| Pioglitazone Hydrochloride Tablets IP 30 mg | GM21077Mfg 2021-08 · Exp 2023-07 | DissolutionDissolution | CDTL KolkataCDSCO lab | Mar 2023 |
| Lactuedge (Lactulose Solution USP) | GA22005Mfg 2022-02 · Exp 2024-01 | Assay and Organic ImpuritiesAssay | CDTL MumbaiCDSCO lab | Mar 2023 |
| Montelukast Sodium Tablets IP 5 mg | GM21075Mfg 2021-08 · Exp 2023-07 | DissolutionDissolution | CDL KolkataCDSCO lab | Nov 2022 |
| Domperidone Tablets IP 10 mg (Domcolic Tablets) | GSM0040Mfg 2021-10 · Exp 2023-09 | IdentificationIdentification | RDTL ChandigarhCDSCO lab | Nov 2022 |
| Sertraline Tablets I.P. 50 mg | GM20105Mfg 2020-11 · Exp 2022-10 | DissolutionDissolution | CDL KolkataCDSCO lab | Aug 2022 |
| Trimetazidine Modified Release Tablets | GM20134Mfg 2020-11 · Exp 2022-10 | DescriptionDescription | CDL KolkataCDSCO lab | Mar 2022 |
| Byzyme (Pepsin & Fungal Diastase Syrup), 200ml | ZA20781Mfg 2020-10 · Exp 2022-03 | AssayAssay | CDL KolkataCDSCO lab | Mar 2022 |
| WARZYME Digestive Enzymes (Pepsin & Fungal Diastase Syrup), 200 ml | AA21036Mfg 2021-06 · Exp 2022-11 | Assay of Pepsin & Fungal DiastaseAssay | CDL KolkataCDSCO lab | Jan 2022 |
| Trimetazidine Modified Release Tablets 35 mg | GM21063Mfg 2021-06 · Exp 2023-05 | Average weightWeight | CDTL MumbaiCDSCO lab | Dec 2021 |
| Trimetazidine Modified Release Tablets 35 mg | GM20173Mfg 2020-11 · Exp 2022-10 | Average weightWeight | CDTL MumbaiCDSCO lab | Dec 2021 |
| Omeprazole Gastro- Resistant Capsules IP 20 mg | GM20126Mfg 2020-11 · Exp 2022-10 | DissolutionDissolution | RDTL GuwahatiCDSCO lab | Dec 2021 |
| Omeprazole Gastro-Resistant Capsules IP 20 mg | GM20033Mfg 2020-03 · Exp 2022-02 | Dissolution & AssayAssay | CDL KolkataCDSCO lab | Jun 2021 |
| Sertraline Tablets IP 50 mg | GM19030Mfg 2019-09 · Exp 2021-08 | DissolutionDissolution | CDTL MumbaiCDSCO lab | May 2021 |
| Prolonged-release Diltiazem Tablets BP 90mg | GM20128Mfg 2020-11 · Exp 2022-10 | DissolutionDissolution | CDTL MumbaiCDSCO lab | Feb 2021 |
| PREGINATE (Doxylamine Succinate & Pyridoxine Hydrochloride Tablets) | ZD19107Mfg 2019-02 · Exp 2021-01 | Description & Assay of Doxylamine SuccinateAssay | CDL KolkataCDSCO lab | Jul 2020 |
| Biodipin 5 (Amlodipine Tablets IP) | ZD19769Mfg 2019-09 · Exp 2021-08 | Related SubstancesRelated substances | CDTL MumbaiCDSCO lab | Feb 2020 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.